Similarities of antiphospholipid antibodies in HIT and APS patients with heparin-platelet factor 4 antibodies

Q4 Medicine Thrombosis Update Pub Date : 2022-05-01 DOI:10.1016/j.tru.2022.100106
Imene Hocine
{"title":"Similarities of antiphospholipid antibodies in HIT and APS patients with heparin-platelet factor 4 antibodies","authors":"Imene Hocine","doi":"10.1016/j.tru.2022.100106","DOIUrl":null,"url":null,"abstract":"<div><p>Heparin-induced thrombocytopenia (HIT) is a prothrombotic autoimmune disorder confirmed by the existence of Heparin-Platelet Factor 4 (HPF4) antibodies. The aim of this work is to study the possible relationship between anti-HPF4 and antiphospholipid antibodies (aPLs) that may explain the discrepancies observed in patients with a suspected HIT (HIT group) with positive immunoassay (HPF4-Elisa) and negative functional assay (heparin-induced platelet aggregation test). So, we performed H-PF4 antibodies research in 31 APS confirmed patients (APL group). All tests performed have been compared to normal controls (n = 34). We found anti-H-PF4 in 7/31 patients of APL group. In parallel, we search for aPLs in 9/34 patients tested positive for anti-HPF4 in HIT group, all of them were positive. All specificities were observed in the two anti-HPF4 positive groups (aβ2GP1 IgM/IgG/IgA, aCL (IgM/IgG/IgA, aPS-PT IgM/IgG). The most associated antibodies with anti-HPF4 are the anti ß2Glycoprotein1 (Odds ratio = 50.1). We suggest that the presence of aPLs in HIT group with anti-HPF4 could be the cause of the discrepancies. In addition, we performed the Heparin Neutralization Assay (HNA) which is specific for anti-HPF4, neutralization was obtained for patients exposed to heparin. Furthermore, we suggest that we should performed a larger cohort to confirm the causal relationship of aPLs and also to expand the tests allowing the differentiation between these autoantibodies.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000104/pdfft?md5=f8055d993cde80746f4ddcf16e8975c3&pid=1-s2.0-S2666572722000104-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis Update","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666572722000104","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic autoimmune disorder confirmed by the existence of Heparin-Platelet Factor 4 (HPF4) antibodies. The aim of this work is to study the possible relationship between anti-HPF4 and antiphospholipid antibodies (aPLs) that may explain the discrepancies observed in patients with a suspected HIT (HIT group) with positive immunoassay (HPF4-Elisa) and negative functional assay (heparin-induced platelet aggregation test). So, we performed H-PF4 antibodies research in 31 APS confirmed patients (APL group). All tests performed have been compared to normal controls (n = 34). We found anti-H-PF4 in 7/31 patients of APL group. In parallel, we search for aPLs in 9/34 patients tested positive for anti-HPF4 in HIT group, all of them were positive. All specificities were observed in the two anti-HPF4 positive groups (aβ2GP1 IgM/IgG/IgA, aCL (IgM/IgG/IgA, aPS-PT IgM/IgG). The most associated antibodies with anti-HPF4 are the anti ß2Glycoprotein1 (Odds ratio = 50.1). We suggest that the presence of aPLs in HIT group with anti-HPF4 could be the cause of the discrepancies. In addition, we performed the Heparin Neutralization Assay (HNA) which is specific for anti-HPF4, neutralization was obtained for patients exposed to heparin. Furthermore, we suggest that we should performed a larger cohort to confirm the causal relationship of aPLs and also to expand the tests allowing the differentiation between these autoantibodies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
HIT和APS患者抗磷脂抗体与肝素血小板因子4抗体的相似性
肝素诱导的血小板减少症(HIT)是一种由肝素-血小板因子4 (HPF4)抗体的存在证实的血栓性自身免疫性疾病。这项工作的目的是研究抗hpf4和抗磷脂抗体(apl)之间可能的关系,这可能解释在疑似HIT患者(HIT组)中观察到的免疫测定(HPF4-Elisa)阳性和功能测定(肝素诱导血小板聚集试验)阴性的差异。因此,我们对31例APS确诊患者(APL组)进行了H-PF4抗体研究。所有试验均与正常对照(n = 34)进行比较。APL组7/31例患者中发现抗h - pf4。同时,我们在HIT组抗hpf4阳性的9/34例患者中搜索apl,均为阳性。两个抗hpf4阳性组(a - β 2gp1 IgM/IgG/IgA, aCL (IgM/IgG/IgA, aPS-PT IgM/IgG)均观察到所有特异性。与抗hpf4最相关的抗体是抗ß2糖蛋白1(优势比= 50.1)。我们认为抗hpf4的HIT组中存在apl可能是导致差异的原因。此外,我们进行了特异性抗hpf4的肝素中和试验(HNA),暴露于肝素的患者获得了中和。此外,我们建议我们应该进行更大的队列来确认apl的因果关系,并扩大允许这些自身抗体之间区分的测试。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Thrombosis Update
Thrombosis Update Medicine-Hematology
CiteScore
1.90
自引率
0.00%
发文量
33
审稿时长
86 days
期刊最新文献
Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults: A population-based cohort study Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO) Usability study of the qLabs® FIB: A new point-of-care system for functional fibrinogen testing Nitrous oxide and VTE – no laughing matter Practical model for implementation of cancer-associated thrombosis prevention in the outpatient setting
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1